Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity

Pharmacological Research

Volumn 68, Issue 1, 2013, Pages 118-124

  Giannantoni, Antonella ^a   Conte, Antonella ^b   Farfariello, Valerio ^a,c   Proietti, Silvia ^a   Vianello, Alberto ^a   Nardicchi, Vincenza ^a   Santoni, Giorgio ^c   Amantini, Consuelo ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Botulinum A toxin; Detrusor overactivity; NGF; p75; TrkA; TRPV1

Indexed keywords

BOTULINUM TOXIN A; NERVE GROWTH FACTOR; PROTEIN P75; PROTEIN TYROSINE KINASE A; VANILLOID RECEPTOR 1;

ADULT; ARTICLE; BLADDER WALL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMETRY; DETRUSOR MUSCLE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MALE; MUSCLE CONTRACTION; NERVE GROWTH FACTOR GENE; OVERACTIVE BLADDER; P75 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE HOMOGENATE; TRPV1 GENE; TYROSINE KINASE A GENE; URODYNAMICS;

ADULT; BOTULINUM TOXINS, TYPE A; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR; TRPV CATION CHANNELS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 84872315599     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.11.009     Document Type: Article

References (26)

1. A. Mangera, K.E. Andersson, A. Aspostolidis, C. Chapple, P. Dasgupta, and A. Giannantoni Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA) European Urology 60 2011 784 795
2. C.P. Smith, M.E. Franks, B.K. McNeil, R. Ghosh, W.C. de Groat, and M.B. Chancellor Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract Journal of Urology 169 2003 1896 1900
3. A. Apostolidis, P. Dasgupta, and C.J. Fowler Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity European Urology 49 2006 644 650
4. M.B. Chancellor, C.J. Fowler, A. Apostolidis, W.C. de Groat, C.P. Smith, and G.T. Somogyi Drug insight: biological effects of botulinum toxin A in the lower urinary tract Nature Clinical Practice Urology 5 2008 319 328
5. A. Conte, A. Giannantoni, S. Proietti, S. Giovannozzi, G. Fabbrini, and A. Rossi Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity European Journal of Neurology 19 2012 725 732
6. A. Apostolidis, R. Popat, Y. Yiangou, D. Cockayne, A.P. Ford, and J.B. Davis Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity Journal of Urology 174 2005 977 982
7. A. Giannantoni, S.M. Di Stasi, V. Nardicchi, A. Zucchi, L. Macchioni, and V. Bini Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity Journal of Urology 175 2006 2341 2344
8. A. Coelho, F. Cruz, C.D. Cruz, and A. Avelino Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action European Urology 61 2012 1178 1184
9. V. Kalsi, A. Apostolidis, G. Gonzales, S. Elneil, P. Dasgupta, and C.J. Fowler Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity European Urology 54 2008 181 187
10. V.Y. Hu, P. Zvara, A. Dattilio, T.L. Redman, S.J. Allen, and D. Dawbarn Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis Journal of Urology 173 2005 1016 1021
11. N. Yoshimura, N.E. Bennett, Y. Hayashi, T. Ogawa, O. Nishizawa, and M.B. Chancellor Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats Journal of Neuroscience 26 2006 10847 10855
12. B. Frias, A. Charrua, A. Avelino, M.C. Michel, F. Cruz, and C.D. Cruz Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input BJU International April 2012 doi: 10.1111/j.1464-410X.2012.11187.x
13. H.T. Liu, M.B. Chancellor, and H.C. Kuo Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection European Urology 56 2009 700 706
14. M. Stoehrer, M. Goepel, A. Kondo, G. Kramer, H. Madersbacher, and R. Millard The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee Neurourology and Urodynamics 18 1999 139 158
15. A. Apostolidis, P. Dasgupta, P. Denys, S. Elneil, C.J. Fowler, and A. Giannantoni European consensus panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report European Urology 55 2009 100 119
16. S. Seki, K. Sasaki, M.O. Fraser, Y. Igawa, O. Nishizawa, and M.B. Chancellor Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats Journal of Urology 168 2002 2269 2274
17. K. Lamb, G.F. Gebhart, and K. Bielefeldt Increased nerve growth factor expression triggers bladder overactivity Journal of Pain 5 2004 150 156
18. H.T. Liu, M.B. Chancellor, and H.C. Kuo Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women BJU International 102 2008 1440 1444
19. H.T. Liu, and H.C. Kuo Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment Urology 72 2008 104 108
20. H.T. Liu, M.B. Chancellor, and H.C. Kuo Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder BJU International 103 2009 1668 1672
21. P. Zvara, and M.A. Vizzard Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord BMC Physiology 28 2007 7 9
22. L. Qiao, and M.A. Vizzard Up-regulation of tyrosine kinase (Trka, Trkb) receptor expression and phosphorylation in lumbosacral dorsal root ganglia after chronic spinal cord (T8-T10) injury Journal of Comparative Neurology 449 2002 217 230
23. M.B. Klinger, and M.A. Vizzard Role of p75NTR in female rat urinary bladder with cyclophosphamide-induced cystitis American Journal of Physiology. Renal Physiology 295 2008 778 789
24. G. Schiavo, M. Matteoli, and C. Montecucco Neurotoxins affecting neuroexocytosis Physiological Reviews 80 2000 717 766
25. A. Blöchl SNAP-25 and syntaxin, but not synaptobrevin 2, cooperate in the regulated release of nerve growth factor Neuroreport 9 1998 1701 1705
26. U.S. Ha, E.Y. Park, and J.C. Kim Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor overactivity Urology 78 2011 721.e1-721.e6